Article 12 · Health & Life Sciences · AGI Future Foundation
Genomic DAO: Consent, Privacy, and Shared Benefit for Genomic Data
Genomic DAO is W3 Series 27. The April 2026 internal W3 series list names “W3 LLC-Genomic DAO — Series 27” and gives no further description, so everything about its scope on this article is a planned focus drawn from what the name implies, labelled as planned. What the name implies is a serious and narrow lane: the governance of genomic data — who consents to its use, under what terms, for what purposes, and with what benefit returning to the people the data came from.
TL;DR
Genomic DAO (S27) is a thin planned DAO whose name implies the governance of genomic data: consent, revocability, and benefit return for the most personal data there is. A genome identifies a person and their relatives, cannot be changed if it leaks, and its interpretation changes as science advances. The DAO would be, first and foremost, a consent and stewardship body, not a data marketplace. It has no anchored metaverse fabric yet, and zero worlds are live on RP1. The series is intended and planned, not formed, funded, or offered.
The work
Genomic DAO is W3 Series 27. The April 2026 internal W3 series list names “W3 LLC-Genomic DAO — Series 27” and gives no further description, so everything about its scope on this article is a planned focus drawn from what the name implies, labelled as planned. What the name implies is a serious and narrow lane: the governance of genomic data — who consents to its use, under what terms, for what purposes, and with what benefit returning to the people the data came from. Genomic data is unlike most data a series might handle, and the planned focus has to start from that fact. A genome identifies a person and their relatives; it cannot be changed if it leaks; and its interpretation changes as science advances, so consent given for one use may not cover a use invented five years later. A DAO in this lane would therefore be, first and foremost, a consent and stewardship body, not a data marketplace. Its job, as planned, would be to hold the line on three questions: did the person whose data this is agree to this specific use, can that agreement be withdrawn, and does the benefit of the use flow back to the people and communities who contributed? Any design that cannot answer those three questions in plain language would fail the Foundation’s public-benefit standard before it started.
The companion series Genome.Blockchain (Series 28) is the natural counterpart: where Genomic DAO would govern the decisions, Genome.Blockchain would hold the verifiable record of them. That division — decisions in one series, records in another — is a planned separation of powers, not an operating arrangement, and it would need a written agreement between the two series defining exactly what each one holds, who can see what, and what happens when they disagree. The neighbouring life-sciences series — BioDAO.blockchain (Series 18), Curable.Blockchain (Series 17), and Diagnostic.X (Series 3) — mark the wider field: biology, cures, and diagnostics. Genomic DAO’s distinct contribution, as planned, is not doing genomics itself but governing how genomic data is used by others.
Because the stakes are high, the bar for this series is higher than for most. Before any data is handled, the series would need counsel on the applicable law in every jurisdiction it touches, a written consent architecture with granular, revocable permissions, a data-minimisation rule (hold the least data needed, for the shortest time needed), and a named human accountable for breaches and for saying no to uses that fail the consent test. It would also need a clear statement that it does not diagnose, treat, or advise individuals on the basis of their genome: screening support and research governance are the planned lane, and clinical claims are outside it. None of these protections exists today. They are requirements the series would have to satisfy to earn the right to operate, and this article lists them so a future reviewer can check whether they were met.
There is also a question of who benefits, and it is the question that separates a stewardship DAO from a data broker with better branding. If genomic data generates value — a research finding, a therapy, a commercial product — who shares in that value, and by what mechanism? A genomic DAO would need its own answer as well: a written benefit-sharing rule, agreed before any data is used, that a contributor can read and understand. No such rule exists for this series today, and no contributor, dataset, or use is verified. Until a rule is written and a first consent is recorded, Genomic DAO is a name awaiting a governance design, and this article keeps it described that way.
The most useful next step for Genomic DAO would be the smallest one that is still checkable: a written consent architecture from a named human steward, covering one use, one dataset, and one withdrawal procedure, reviewed by counsel. A genomic DAO that cannot describe one consent cannot be trusted with a thousand, and a series that will not name who is accountable for a breach has not yet understood the data it claims to govern. Until that document exists, the honest size of Genomic DAO is a name, a number, and a direction — and this article leaves it at that.
Metaverse connection
Genomic DAO has no anchored metaverse fabric yet. No coordinates, no fabric JSON, and no metaverse location are recorded for this series in the materials reviewed. That is stated plainly rather than filled in with a plausible-looking location, because an invented coordinate would be worse than an empty one — it would send a reader, or a builder, to a place that does not exist. Zero worlds are live on RP1.
What would be needed for a metaverse presence is the same sequence that the anchored series went through, and it has not started for Genomic DAO: a decision about what a world for this series would be for, a fabric definition published at a checkable address, the assets that fabric references hosted at the paths it expects, and a verified render in Artemis. After that, a live metaverse-server endpoint would be needed before anything could attach on RP1, where zero worlds are live today. None of those steps has been taken, and none is claimed here.
It is worth asking whether a genomic-data DAO needs a metaverse world at all, and the honest answer is that it probably does not need one first — and may never need one. A consent and stewardship body’s first home is a consent architecture, a data-minimisation rule, and a named accountable human — not a world. A world could one day host education about genomic data rights, but only after the series could say what it governs and how withdrawal works. Building the world first would put the venue ahead of the governance, and this article does not recommend that order.
What exists today vs what is planned
What exists today
One thing is verified: the name and number, Genomic DAO, Series 27, in the April 2026 internal W3 series list. Only repo: genomic-site, a landing stub for the genomic-go-platform, AI agent swarms for genomics, proteomics and drug discovery per the repo; the S27/S28 question stays flagged. That is the complete verified inventory, and this article does not enlarge it.
What is planned
Everything else is planned, not existing: the formation of W3 LLC and the designation of this series; a human Steward Council and operating rules; a written consent architecture with granular, revocable permissions; a data-minimisation rule; a named human accountable for breaches; a benefit-sharing rule; any funding; and any metaverse presence. Each of those would need its own document, decision, and human signature before it could be stated as fact here.
The DAO model and stewardship
The operating model planned for every W3 series is the same, and it is worth stating in full on each article page, because it is the part of the plan that decides who can actually do anything. In the intended model, Genomic DAO would be DAO-managed day to day: agents operate the routine work within limits set by humans, and a human Steward Council decides everything that carries a legal, financial, or doctrinal consequence. Agents prepare; humans execute. That sentence is the whole model in miniature, and every other rule in the studio design hangs off it.
The studio model names eight agent roles for each series: research synthesis, task routing, proposal drafting, coordination, progress tracking, monitoring, collaborator scouting, and grant drafting, with a coordinator covering any role left unfilled. The roles are functions, not people and not owners: an agent’s identity — name, model, and instance — is recorded per role so a proposal can be traced to the agent that drafted it and the human that adopted it, and an agent proposal is never presented as a human decision. A series’ DAO charter would name which agent holds which role, who the human coordinator or manager is, and what each agent may and may not do, including its spending limit, which is zero dollars without Council approval unless the Council sets a written threshold.
The human gate is where the model gets its teeth. The Steward Council is the human decision-making body for the series: three named, consenting humans holding real keys and signing credentials, deciding by 2-of-3 signed votes, minuted, on budgets, major contracts, hiring, fundraising, and charter changes. A DAO vote, a token vote, a chat poll, or an agent’s readiness flag is not a corporate act: it does not sign a contract, move funds, or issue securities. Only the council, with signed authority, does that. Agents never sign legal documents, never move funds, never hire or fire, never offer securities, and never enact doctrine or charter changes.
Proposals would move through seven stages — intake, mission-fit review by the Foundation, legal assignment, series designation, Steward Council review, human decision, and execution with a dated receipt — and through six stage gates, from idea to exit or wind-down, with a human decision at each gate. Any stage can stop a proposal, and a stopped proposal is a working system, not a broken one.
None of this is operating for Genomic DAO today. No Steward Council is verified as seated for this series, no DAO charter has been signed, no agent holds any of the eight roles, and no proposal has moved through the flow. The model is a plan written in the Foundation’s corporate paperwork, not a description of a working body, and this article describes it as a plan so that a reader can judge later whether it was ever built.
How it fits the mission
Genomic DAO sits in the third tier of the Foundation’s intended three-tier architecture. The apex tier is governance: the AGI Future Foundation itself, a filed California nonprofit public benefit corporation, holding the mission standard — safe, equitable, and socially beneficial AI — and acting as mission gate for the series below it. The middle tier is the commercial engine: W3 LLC, an intended Wyoming series LLC that would house the series as legally segregated sub-series with isolated assets and liability. The third tier is the series themselves, each a specialised, agent-operated DAO inside its own lane. Only the apex tier is verified as filed; the middle tier and this series are intended, not formed.
Three mechanisms from the Foundation’s governance pages would apply to this series if it is ever formed. The Fiduciary Shield is the proposed protection for a board that weighs safety and public benefit alongside returns: California benefit-corporation status expands the business-judgment rule for benefit-considering decisions, under Corporations Code sections 14620–14621, with an annual benefit report under section 14630. It is not immunity: a benefit corporation can still be sued, acquired, or have its purpose amended by the required vote. Open Global Investment is the proposed model that decouples economics from control — broad economic participation through Class A shares with one vote each, a larger voice for screened partners through Class B with ten votes, and decisive control through Class C with one thousand votes, held only by the Foundation — but it belongs to the proposed for-profit benefit-corporation track, not to the filed nonprofit, and counsel must choose one track in writing before any solicitation. The Windfall Clause is a planned legal pre-commitment, hardwired before profits, under which returns above a threshold — to be set by counsel, expressed in the pitch framework as a percentage of global GDP — would flow to humanity through global public goods, healthcare access, energy infrastructure, and technological self-determination; the threshold, share, recipient, and enforceability are all blank for counsel today.
The Foundation’s fundraising, as filed, is donation and grant only. Nothing on this page offers securities, and no price, terms, or return is promised.
Open questions
- Did the person whose data this is agree to this specific use, can that agreement be withdrawn, and does the benefit flow back to the people who contributed?
- What does a granular, revocable consent architecture look like for genomic data — and who writes it, with which counsel?
- What is the data-minimisation rule: the least data needed, for the shortest time needed, and who enforces it?
- Who is the named human accountable for a breach, and for saying no to a use that fails the consent test?
- How do Genomic DAO (S27) and Genome.Blockchain (S28) divide decisions from records — and what happens when they disagree?
- What would have to be true — which filing, which council, which document — before Genomic DAO could claim its first real consent?
What is verified

Checked against the BioDAO tools inventory of 2026-11-06/07, which re-checked all 90 public repositories in the Foundation account live. For Genomic DAO, one substantive-but-thin repository and one landing stub are verified. genomic-go-platform is a fork of an outside platform, AGI-Corporation/genomic-go-platform, missed by the 2026-11-05 review of 56 repositories. Its 651-line README describes a large platform — 35 agent swarms, about 75 agents per swarm, AlphaFold3, molecular dynamics, compound generation with ADMET validation, and swarm categories including drug discovery, longevity, fertility, and regenerative medicine — but the code is far thinner than the README: about six source files, one test file, and seven documents, last committed 2026-03-01, with no verified deployment, demo, or run status. Its scale claims are the fork's claims, not verified built capacity. genomic-site is a six-line landing stub only. The subdomain genomic.agifuturefoundation.org was unreachable by curl in the check and is not presented as live. The split with S28 Genome.Blockchain is unresolved: these artifacts are cited here under S27 and are not assigned to S28. Longevity appears in the platform README as a claimed swarm category, not as verified built capacity, and this article claims no longevity outcome, therapy, or timeline. All verified BioDAO tools are listed on the BioDAO tools page.
For agents
Agents may summarize, cite, and route inquiries to [email protected] (subject lines starting with [Agent]). Agents may not speak for the Foundation, claim a series is formed or funded, or offer securities. Every substantive step goes through a named human.
Series page: Genomic DAO (S27). Related articles: BioDAO.blockchain DAO (Article 11) · Genome.Blockchain (Article 13) · Diagnostic.X (Article 04)
Contact
Questions about Genomic DAO, or about the Foundation’s work in this category, go to [email protected]. Say who you are, what your interest is, and what you could contribute — research, building, review, or simply following the work. A reply, if one comes, will come from a human. This page is not an offer of securities and not a solicitation of funds: no price, terms, or return is promised, and no funding is being sought for this series. Nothing on this page is legal, tax, or financial advice.
← Previous: BioDAO.blockchain DAO | Next: Genome.Blockchain →